SCHEMBL19631439

SCHEMBL19631439

O=C(NO)c1ccc(CNc2cccc3nccnc23)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 20/20 1.00
HDAC1 Q13547 5/20 0.73
HDAC3 O15379 3/20 0.73
HDAC2 Q92769 3/20 0.73
HDAC4 P56524 2/20 0.73
HDAC7 Q8WUI4 2/20 0.73
HDAC10 Q969S8 2/20 0.73
HDAC11 Q96DB2 2/20 0.73
HDAC8 Q9BY41 2/20 0.73
HDAC9 Q9UKV0 2/20 0.73
HDAC5 Q9UQL6 2/20 0.73
NCOR2 Q9Y618 2/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29412220 0.85 HDAC6 (1.00) HDAC6HDAC1HDAC3HDAC2HDAC4
SCHEMBL31424931 0.85 HDAC6 (1.00) HDAC6HDAC1HDAC3HDAC2HDAC4
SCHEMBL19631273 0.85 HDAC6 (1.00) HDAC6HDAC1HDAC3HDAC2HDAC4
SCHEMBL24522644 0.84 HDAC6 (0.71) HDAC6HDAC1HDAC3HDAC2HDAC4
SCHEMBL19617676 0.84 HDAC6 (1.00) HDAC6HDAC1HDAC3HDAC2HDAC4
SCHEMBL19631379 0.84 HDAC6 (0.72) HDAC6HDAC1HDAC3HDAC2HDAC4
SCHEMBL21356136 0.80 HDAC6 (0.89) HDAC6HDAC1HDAC3HDAC2HDAC4
SCHEMBL19631337 0.80 HDAC6 (1.00) HDAC6HDAC1HDAC3HDAC2HDAC4
SCHEMBL23951038 0.76 HDAC6 (0.61) HDAC6HDAC1HDAC3HDAC2HDAC4
SCHEMBL19616630 0.75 HDAC6 (1.00) HDAC6HDAC1HDAC3HDAC2HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346563-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN UNIV TAIPEI MEDICAL (TW) 2025-11-13 US disclosed
US-11427544-B2 Histone deacetylase 6 inhibitors and use thereof TAIPEI MEDICAL UNIVERSITY (TW) 2022-08-30 US disclosed
US-20220251043-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN TAIPEI MEDICAL UNIVERSITY (TW) 2022-08-11 US disclosed
EP-3458444-B1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF UNIV TAIPEI MEDICAL (TW) 2022-06-22 EP disclosed
EP-3458444-B1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF UNIV TAIPEI MEDICAL (TW) 2022-06-22 EP disclosed
WO-2021013163-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN TAIPEI MEDICAL UNIVERSITY (CN) 2021-01-28 WO disclosed
US-20190284141-A1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF DCB-USA LLC (US) 2019-09-19 US disclosed
US-20190284141-A1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF DCB-USA LLC (US) 2019-09-19 US disclosed
WO-2017200966-A1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF DCB-USA LLC (US) 2017-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284141-A1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF HDAC1, HDAC11, HDAC7 HDAC6 7/4885HDAC1 1/4885HDAC3 6/4885
US-20250346563-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN HDAC1, HDAC3, HDAC5 HDAC6 4/4885HDAC1 1/4885HDAC3 2/4885
US-20220251043-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN HDAC1, HDAC3, HDAC2 HDAC6 9/4885HDAC1 1/4885HDAC3 2/4885
US-11427544-B2 Histone deacetylase 6 inhibitors and use thereof HDAC1, HDAC11, HDAC7 HDAC6 7/4885HDAC1 1/4885HDAC3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.